Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: A meta-analysis

Journal of Invasive Cardiology

Volumn 20, Issue 6, 2008, Pages 292-295

  Ebrahimi, Ramin ^a,b   Saleh, Jahandar ^a   Toggart, Edward ^a,b   Shah, Atman P ^b   Azmoon, Shahdad ^b   Babaei, Hormoz ^a   Lee, James ^b   Smith, Ryan ^b   Movahed, M Reza ^c   Rubin, Stanley A ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL DOCUMENTATION; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 46749085975     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Kejkshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
2. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study. N Engl J Med 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-1622.
5. The LIPID Study Group. Long-term intervention with pravastatin in ischemic disease. N Engl J Med 1998;339:1349-1357.
6. Ridker PM, Rifai N, Clearfield M, et al. Air Force/Texas coronary Atherosclerosis Prevention Study Investigators. Statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
7. Cannon CP, Braunwald E, McCabe CH, Prove IT-TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med 2004;350:1495-1504.
8. Schwartz GG, Olsson AG, Ezekowitz MD, et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndrome. JAMA 2001; 285: 1711-1718.
9. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-1828.
10. Mulukutla SR, Marroquin OC, Smith C, et al. Effect of statin therapy prior to elective percutaneous coronary intervention of frequency of periprocedural myocardial injury. Am J Cardiol 2004;94:1363-1368.
11. Hermann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-2183.
12. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcomes. Catheter Cardiovasc Interv 2004;62:193-197.
13. Pasceri V, Patti G, Nusca A, Pristipino C, ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA Study. Circulation 2004;110:674-678.
14. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percuatneous coronary inteventions. Circulation 2003;107:1750-1756.
15. Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors Int J Clinic Practice 2006;60:993-1002.
16. Chan A, Bhatt D, Chew D, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
18. Nakata S, Tsutsui M, Shimokawa H, et al. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway. Arterioscler Thromb Vasc Biol 2007;27:92-98.
19. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioslcer Thromb Vasc Biol 1998;18:1671-1678.
20. Albert MA, Staggers J, Chew P, Ridker PM, PRINCE Investigators. The pravastatin inflammation CRP evaluation (PRINCE) rationale and design. Am Heart J 2001;141:893-898.